Lakefront Biotherapeutics N.V.

Lakefront Biotherapeutics N.V.

LKFT - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$2.19B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Lakefront Biotherapeutics N.V.Lakefront Biotherapeutics N.V.4.1-24%2.4-
$35.50

Target Price by Analysts

6.6% upsideLakefront Biotherapeutics N.V. Target Price DetailsTarget Price

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$2.19 Billion
Enterprise Value$2.09 Billion
Earnings per Share$4.87
Beta0.12
Outstanding Shares65,655,167

Return

Return on Equity24.22%ROE
Return on Assets23.76%
Return on Invested Capital17.92%

Valuation & Multiples

P/E Ratio4.08P/E Ratio
PEG-4.14PEG
Price to Sales2.38Price to Sales
Price to Book Ratio0.67Price to Book Ratio
Enterprise Value to Revenue2.26
Enterprise Value to EBIT3.54
Enterprise Value to Net Income2
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 11, 2026
EPS
-$0.04
Est. -$0.37
Revenue
$8.39 M
Est. $5.86 M

Next Earnings Call

Expected Date
February 24, 2027
EPS Estimate
-$0.70
Consensus analyst estimate
Revenue Estimate
$7.96 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Galapagos NV

452 employees
CEO: Onno van de Stolpe

Galapagos N.V. is a fully-integrated biopharmaceutical firm dedicated to discovering, developing, and bringing to market innovative therapies for conditions where patient needs are largely unaddressed. The company boasts a robust pipelin...

Questions & Answers